Targeted degradation of CBP/p300 by CBPD-409 exhibits robust anti-myeloma activity.
Authors: Corradini S, Maksimos M, Azab F, Arsalani S, Nwarunma E, Watt G, Soutar R, Powell M, Henderson R, Travers J, Chen Z, Wang S, Azab AK, Williams MTS
Journal: Leukemia
addiction recovery
mental health
open access